SummaryRMgm-387
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 20088947 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | clone 1.1 |
Other information parent line | 17XNL is a non-lethal strain of P. yoelii |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | A.S.I. Aly; S.H.I. Kappe |
Name Group/Department | Not applicable |
Name Institute | Seattle Biomedical Research Institute, University of Washington |
City | Seattle |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-387 |
Principal name | Pynt1- |
Alternative name | Pynt1- EP1; Pynt1- EP2 |
Standardized name | |
Is the mutant parasite cloned after genetic modification | No |
top of page | |
Phenotype | |
Asexual blood stage | Asexual blood stages show a strongly reduced growth and multiplication. BALB/c mice infected with 50 Pynt1- did not show detectable parasitemia by thin blood smears up to 30 days p.i. Mice infected with 5000 Pynt1- became patent at day 8 p.i. with a peak average parasitemia of 2.4 % at day 12 p.i.In contrast, mice infected with 50 and 5000 wild-type BS parasites became patent at days 4 and 2 p.i., respectively, and showed average peak parasitemias of 30.2% and 36.5% at days 12 and 11 p.i., respectively. |
Gametocyte/Gamete | It is reported that mutant parasites show an inefficient micro- and macrogametocytogenesis and a delayed male gamete exflagellation (however, no data is shown). |
Fertilization and ookinete | Not tested |
Oocyst | No oocyst formation |
Sporozoite | No oocyst and sporozoite formation |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation It was not possible to clone Pynt1- parasites by limited dilution using 1, 5, 10 and 50 parasites per mouse. Only after starting with 100 Pynt1- parasites as the intravenous inoculum, 15–20% of the recipient mice became patent 11–14 days post inoculation (p.i.). Immunization of inbred and outbred mouse strains with a single low dose of Pynt1- blood stages (50-100 parasites) did not induce any patent infections and conferred complete sterile protection against lethal blood stage and sporozoite challenges. In order to investigate which type of immune responses are mediating sterile protective immunity the following mice strains were infected: alpha–beta T cell-deficient mice (Tcra(tm1Mom)/J), which lack the alpha–beta T-cell receptor, and mature B cell-deficient mice [Igh-6(tm1Cgn)/J]. Both transgenic mouse strains are in the C57BL/6 genetic background. Both transgenic mouse strains were not protected and developed lethal parasitemias, which were first detected in blood smears at day 4 after challenge. WT C57BL/6 control mice showed complete protection. These analyses indicate that both cellular and humoral immune responses are essential for sterile protection. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1360100 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1347200 | ||||||||||||||||||||||||
Gene product | nucleoside transporter 1 | ||||||||||||||||||||||||
Gene product: Alternative name | NT1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |